But if US pharma giants are focused on building impenetrable thickets around every successful drug class, how can smaller players co-own, license, or even innovate in the periphery without facing immediate litigation
Proc Natl Acad Sci 79(2):345349 Ma Y, Huang Y, Yan L, Gao M, Liu D (2013) Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance
Findings in the lung are model-dependent
Diabetes, Obesity and Metabolism, 22 (6), 891903
Diet does much of this work (see below), and some people also consider a targeted supplement
Increasing the number of intestinal endocrine L-cells According to the impairment of L-cells development in T2DM, a promising strategy for treating T2DM is to increase the number of L-cells in the intestine, thereby increasing the production of GLP-1